Indian drugmakers launch cheaper versions of Ozempic and Wegovy.
Indian pharmaceutical companies are flooding the market with cheaper generic versions of Novo Nordisk’s popular diabetes and weight-loss drugs, Ozempic and Wegovy. This move is set to significantly reduce treatment costs, with savings estimated at approximately 70%.
Several major Indian drugmakers have already launched their semaglutide-based medications, and the market is expected to see over 50 different brands competing for market share. The introduction of these affordable alternatives could transform access to these treatments in India.
The availability of cheaper options may increase accessibility for patients who previously could not afford the high cost of the original branded drugs. This development also poses a challenge to Novo Nordisk, as it faces competition from local manufacturers offering similar products at significantly lower prices.
About the Author
